Validation of CPS+EG, Neo-Bioscore, and Modified Neo-Bioscore Staging Systems After Preoperative Systemic Therapy of Breast Cancer: Protocol of a Retrospective Multicenter Cohort Study in China

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2018 Oct 9

PMID 30296013

Citations 4

Authors

Ling Xu

Zhuo Zhang

Qianxin Liu

Bin Zhou

Yinhua Liu

Qian Xiang

Sainan Zhu

Xuening Duan

Yimin Cui

Affiliations

Soon will be listed here.

Abstract

Prognostic assessment after preoperative systemic therapy (PST) is critical to develop a therapeutic strategy for breast cancer management. Currently, a clinical-pathologic staging system that incorporates ER status and nuclear grading (CPS + EG), and the Neo-Bioscore system that includes HER2 status into CPS + EG, are used to predict outcomes in patients with breast cancer after PST. While HER2-positive is recognized as a favorable factor in the Neo-Bioscore system based on results in patients administered one year of trastuzumab as anti-HER2 therapy, most HER2-positive cases have difficulty accessing anti-HER2 treatment in China. Therefore, it is crucial that a modified Neo-Bioscore staging system is developed that incorporates an additional factor of poor prognosis, HER2-positive status without trastuzumab treatment, to determine accurate prognosis. We propose a retrospective multicenter cohort study in China to validate CPS + EG, Neo-Bioscore, and the modified Neo-Bioscore system and determine the accuracy of prediction. Primary breast cancer patients without metastasis treated with PST and surgery in academic institutions or hospitals of provincial level in China will be included. Disease-free, disease specific, and overall survival will be calculated using the Kaplan-Meier Method, stratified by CPS + EG, Neo-Bioscore, and the modified Neo-Bioscore staging system. Areas under the curve of each staging system will be calculated. Multivariate analysis using Wald testing and maximum likelihood estimates in a Cox proportional hazards model will be conducted.

Citing Articles

External verification and improvement of the Neo-Bioscore staging system in a Chinese cohort.

Geng R, Min N, Zheng Y, Hong C, Wu R, Wu H Ann Transl Med. 2022; 10(11):626.

PMID: 35813331 PMC: 9263773. DOI: 10.21037/atm-21-6738.

Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer.

Zhang Z, Zhang H, Li C, Xiang Q, Xu L, Liu Q Thorac Cancer. 2021; 12(24):3396-3406.

PMID: 34751517 PMC: 8671904. DOI: 10.1111/1759-7714.14219.

Assessment of CPS + EG, Neo-Bioscore and Modified Neo-Bioscore in Breast Cancer Patients Treated With Preoperative Systemic Therapy: A Multicenter Cohort Study.

Xu L, Liu Y, Fan Z, Jiang Z, Liu Y, Ling R Front Oncol. 2021; 11:606477.

PMID: 33796452 PMC: 8009183. DOI: 10.3389/fonc.2021.606477.

Comparison of the performance of four staging systems in determining the prognosis of breast cancer among women undergoing neoadjuvant chemotherapy.

Soares I, Bello M, Bergmann A, Thuler L Breast Cancer Res Treat. 2021; 187(2):547-555.

PMID: 33417086 DOI: 10.1007/s10549-020-06077-4.

References

Li J, Wang S, Wang Y, Wang X, Wang H, Feng J . Disparities of Trastuzumab Use in Resource-Limited or Resource-Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real-World Study from China. Oncologist. 2017; 22(11):1333-1338. PMC: 5679829. DOI: 10.1634/theoncologist.2017-0088. View

Buzdar A, Ibrahim N, Francis D, Booser D, Thomas E, Theriault R . Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23(16):3676-85. DOI: 10.1200/JCO.2005.07.032. View

Zhou B, Xu L, Ye J, Xin L, Duan X, Liu Y . The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2-Enriched Subtype Breast Cancer, a Retrospective Analysis. Anticancer Res. 2017; 37(8):4615-4621. DOI: 10.21873/anticanres.11862. View

Boons C, Wagner C, Hugtenburg J . Guideline Adherence Regarding the Use of Expensive Drugs in Daily Practice: The Examples of Trastuzumab in Breast Cancer and Bortezomib in Multiple Myeloma. Oncol Res Treat. 2016; 39(7-8):417-22. DOI: 10.1159/000447280. View

Jones R, Salter J, AHern R, Nerurkar A, Parton M, Reis-Filho J . Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2009; 119(2):315-23. DOI: 10.1007/s10549-009-0329-x. View

Goldhirsch A, Wood W, Coates A, Gelber R, Thurlimann B, Senn H . Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011; 22(8):1736-47. PMC: 3144634. DOI: 10.1093/annonc/mdr304. View

Xu L, Duan X, Zhou B, Liu Y, Ye J, Liu Z . Validation of the CPS+EG and Neo-Bioscore staging systems after preoperative systemic therapy for breast cancer in a single center in China. Breast. 2018; 40:29-37. DOI: 10.1016/j.breast.2018.03.010. View

Choi M, Park Y, Ahn J, Im Y, Nam S, Cho S . Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems. Breast Cancer Res Treat. 2016; 160(3):475-489. DOI: 10.1007/s10549-016-4008-4. View

Buzdar A, Valero V, Ibrahim N, Francis D, Broglio K, Theriault R . Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized.... Clin Cancer Res. 2007; 13(1):228-33. DOI: 10.1158/1078-0432.CCR-06-1345. View

10.

Lee S, Sohn G, Kim J, Chung I, Lee J, Kim H . A retrospective prognostic evaluation analysis using the 8th edition of the American Joint Committee on Cancer staging system for breast cancer. Breast Cancer Res Treat. 2018; 169(2):257-266. PMC: 5945740. DOI: 10.1007/s10549-018-4682-5. View

11.

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5):403-10. DOI: 10.1111/j.1365-2559.1991.tb00229.x. View

12.

Wang S, Long J, Hurria A, Owusu C, Steingart R, Gross C . Cardiovascular events, early discontinuation of trastuzumab, and their impact on survival. Breast Cancer Res Treat. 2014; 146(2):411-9. DOI: 10.1007/s10549-014-3029-0. View

13.

Piccart-Gebhart M, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I . Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1659-72. DOI: 10.1056/NEJMoa052306. View

14.

Masuda N, Lee S, Ohtani S, Im Y, Lee E, Yokota I . Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy. N Engl J Med. 2017; 376(22):2147-2159. DOI: 10.1056/NEJMoa1612645. View

15.

Untch M, Rezai M, Loibl S, Fasching P, Huober J, Tesch H . Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010; 28(12):2024-31. DOI: 10.1200/JCO.2009.23.8451. View

16.

Ogston K, Miller I, Payne S, Hutcheon A, Sarkar T, Smith I . A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003; 12(5):320-7. DOI: 10.1016/s0960-9776(03)00106-1. View

17.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

18.

Dacosta Byfield S, Buck P, Blauer-Peterson C, Poston S . ReCAP: Treatment Patterns and Cost of Care Associated With Initial Therapy Among Patients Diagnosed With Operable Early-Stage Human Epidermal Growth Factor Receptor 2-Overexpressed Breast Cancer in the United States: A Real-World Retrospective Study. J Oncol Pract. 2015; 12(2):159-67. DOI: 10.1200/JOP.2015.004747. View

19.

Mittendorf E, Jeruss J, Tucker S, Kolli A, Newman L, Gonzalez-Angulo A . Validation of a novel staging system for disease-specific survival in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011; 29(15):1956-62. PMC: 3107758. DOI: 10.1200/JCO.2010.31.8469. View

20.

Montagna E, Bagnardi V, Viale G, Rotmensz N, Sporchia A, Cancello G . Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol. 2014; 26(2):307-13. DOI: 10.1093/annonc/mdu528. View